Back

Role of ivabradine in development of new onset atrial fibrillation in acute coronary syndrome patients

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Abdallah Almaghraby

Ibrahim bin Hamad Obaidullah, Ras Al Khaimah (United Arab Emirates)

4 More presentations in this session

Presentation thumbnail
Discussant: Best Posters in new targets in cardiovascular drug assessment
Presentation thumbnail
Individual-specific corrected QT interval (QTcI) obtained from ECGs recorded at fixed timepoints versus QTcI derived using a wider range of stable heart rates from 24-hour Holter recordings
Doctor R. Turner (Durham, US)
Abstract Slides
Presentation thumbnail
Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease
Associate Professor S. Skrtic (Soborg, SE)
Abstract
Presentation thumbnail
Lack of low-density lipoprotein cholesterol (LDL-C) goal attainment among high-risk patients using high or moderate intensity statin therapy in Germany
Doctor M. Hatz (Munich, DE)
Abstract Slides

Access the full session

Session thumbnail
Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources